What is Ascletis Pharma?
Ascletis Pharma Inc. operates as a fully integrated biotechnology enterprise, distinguished by its commitment to addressing significant unmet medical needs through advanced scientific methodologies. By leveraging Artificial Intelligence-assisted Structure-Based Drug Discovery and an Ultra-Long-Acting Platform, the company develops a diverse portfolio of small molecules and peptides. These innovations are specifically targeted at chronic weight management and complex metabolic disorders. As a publicly traded entity on the Hong Kong Stock Exchange, Ascletis bridges the gap between high-level laboratory research and commercial-scale therapeutic delivery, serving a critical role in the healthcare ecosystem for both providers and patients globally.
How much funding has Ascletis Pharma raised?
Ascletis Pharma has raised a total of $255M across 4 funding rounds:
Series A
$100M
Private Equity
$35M
Unspecified
$20M
Series B
$100M
Series A (2011): $100M, investors not publicly disclosed
Private Equity (2015): $35M led by Tasly Pharmaceuticals, Inc and CBC Group
Unspecified (2015): $20M supported by Goldman Sachs
Series B (2017): $100M featuring CBC Group, Tasly Pharmaceuticals, Inc, and Goldman Sachs
Key Investors in Ascletis Pharma
CBC Group
CBC Group is a prominent healthcare-dedicated investment firm in Asia, specializing in platform-building and buyout opportunities within the pharmaceutical, biotech, and medtech sectors.
Tasly Pharmaceuticals, Inc
Tasly Holding Group is a global conglomerate focused on pharmaceutical manufacturing and distribution, maintaining a diverse portfolio of medical and scientific innovations.
Goldman Sachs
Goldman Sachs is a leading global investment banking and management firm that provides comprehensive financial services, including strategic advisory and capital market support.
What's next for Ascletis Pharma?
Looking ahead, the infusion of capital from recent financing rounds positions Ascletis Pharma to scale its operational capabilities and expedite the clinical progression of its lead candidates. The strategic focus remains on maximizing the utility of its AI-driven discovery engine to shorten development cycles for chronic disease therapeutics. By maintaining a disciplined approach to capital allocation and leveraging its established partnerships with global financial institutions, Ascletis is well-equipped to navigate the competitive pharmaceutical market. Future growth will likely be driven by the successful commercialization of its pipeline and the potential for further expansion into international markets, ensuring long-term value creation for stakeholders and improved health outcomes for patients.
See full Ascletis Pharma company page
